Endothelial cell activation mediated by berythractivase

CHUDZINSKI-TAVASSI AM; NEGROTTO S; D'ATRI LP; BEZERRA DA SILVA M; POZNER RG; LAZZARI MA; SCHATTNER M

Pirenópolis, Brasil

Simposio; VII Simpósio da Sociedade Brasileira de Toxinologia; 2002

The venom of Bothrops erythromelas, a species which occurs in northeastern Brazil, has a much higher procoagulant activity than other Bothrops species. Berythractivase is a 78 kDa metalloproteinase purified from B. erythromelas venom and its primary structure has been deduced from cDNA. In vitro, berythractivase is a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs and its primary structure has been deduced from cDNA. In vitro, berythractivase is a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs Berythractivase is a 78 kDa metalloproteinase purified from B. erythromelas venom and its primary structure has been deduced from cDNA. In vitro, berythractivase is a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs and its primary structure has been deduced from cDNA. In vitro, berythractivase is a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vWF) by 153% (p<0.05, n=4) and up-regulated prostacyclin (Control 1.3±0.2 vs Brazil, has a much higher procoagulant activity than other Bothrops species. Berythractivase is a 78 kDa metalloproteinase purified from B. erythromelas venom and its primary structure has been deduced from cDNA. In vitro, berythractivase is a prothrombin activator. Since Bothrops snake venoms induce local inflammatory lesions and disseminated intravascular coagulation (DIC), we have evaluated the effect of erythractivase on human umbilical vein endothelial cells (HUVEC). Morphological alterations were observed in HUVEC after 1 h of incubation with berythractivase (5 ìg/ml). Flow cytometry showed that berythractivase (Be) increased the expression of ICAM-1 (Control 12±1 vs Be 21±3 arbitrary fluorescence units (AFU), p<0.05, n=6) and E-selectin (Control 7±1 vs Be 25±1 AFU, p<0.05, n=4), without modifying the levels of VCAM-1 (Control 4±1 vs Be 4±0.5 AUF, n=4). Berythractivase increased the release of von Willebrand Factor (vW